In endocrine-resistant HR + breast cancer, combination therapy with Fulvestrant yielded encouraging activity: partial responses were observed in both CDK4/6i-pretreated (objective response rate: 6.7%) and CDK4/6-naïve cohorts (22.7%), highlighting its potential to overcome CDK4/6 resistance (Yap et al., 2025). The gene discussed is CDK4; the disease is breast carcinoma.